ClinicalTrials.gov
Cure8 trial brief
Why This Matters
Researchers are testing whether blocking three inflammation pathways at once can reduce tissue inflammation more than single drugs. If ex vivo results show stronger effects, it could guide development of multi-target therapies for people who don't respond to current biologics.
Who Should Pay Attention
Researchers and clinicians studying IBD mechanisms and new therapies; patients on biologic therapies or with refractory disease who follow emerging drug research.
Study Snapshot
Story typeClinical Reference
Trial phaseNA
Enrollment30 participants
Study statusNot_yet_recruiting
Source depthTrial registry record
What To Know
This is a registered interventional ex vivo clinical study (not yet recruiting) testing whether simultaneous inhibition of TL1A, IL-23, and α4β7 pathways with a tri-specific inhibitor (ATTO-1091) produces stronger anti-inflammatory effects in mucosal biopsies from people with Ulcerative Colitis, Crohn's Disease, and non-IBD controls.
Biopsies collected during routine colonoscopy will be cultured and compared across conditions (tri-specific inhibitor, individual pathway inhibitors -- listed in the record as sulisokibart/tulisokibart?, risankizumab, vedolizumab -- and vehicle controls) with molecular readouts including ELISA and RNA sequencing.
Participant involvement is limited to extra biopsies and a small blood draw during a scheduled colonoscopy; no investigational product is given to participants in vivo.
Keep In Mind
This is an ex vivo laboratory study using biopsies and molecular assays — not a trial of giving the drug to patients. Results will show biological responses in tissue samples, which can suggest but do not prove clinical benefit. The record is a trial registry entry (not a peer-reviewed paper); planned methods include RNA-seq and ELISA and laboratory blinding is specified.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorPhoenixLAB srls
Trial IDNCT07824726
Study typeInterventional
Trial phaseNA
Enrollment30 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedSep 17, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
How Biologics Are Changing the Global Burden of Inflammatory Bowel Disease: A Review.
Biologics and newer small molecules have markedly changed IBD care and outcomes for many patients, but their population-level impact depends on access, cost, and how they are used. Understanding this helps patients and...
Highlights of the 2026 European Crohn's and Colitis Conference: redefining the IBD care continuum.
ECCO 2026 presented multiple studies that could change IBD care across prevention, medical therapy (including pediatric data), complication‑directed strategies (perianal fistula), and technology‑assisted monitoring....
Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)
People with IBD who don’t respond well to ustekinumab may need alternative options. This study will track how patients fare after switching to guselkumab in routine clinical care and report rates of deep remission at one...